Jubilant Pharmova Limited (NSE: JUBLPHARMA) reported a Revenue from Operations of ₹1,533.22 Crores, a boost of 18% growth from the previous year. The Net Loss for the business is ₹16.04 Crore from the profit of ₹50.80 Crore year on year. Earnings per Share is -₹0.98 for this quarter.
Jubilant Pharmova Limited Q3 FY23; Revenue Increased By 18%
Tags: pharmaceuticals
Related Post
- Edelweiss Financial Services Limited charts multi-year growth across asset management and insurance businesses
Edelweiss Financial Services Limited (NSE: EDELWEISS, BSE: 532922) presented a multi-year snapshot of growth across…
-
Aarti Pharmalabs Limited reports sequential margin recovery in Q3 FY26 as CDMO transit impact weighs on revenue
Aarti Pharmalabs Limited (NSE: AARTIPHARM, BSE: 543748) reported a sequential improvement in operating performance in…
-
Earnings Summary: G R Infraprojects Limited reports higher Q3 FY26 income as execution accelerates; margins stable
G R Infraprojects Limited (NSE: GRINFRA, BSE: 543317) reported higher income for the quarter ended…